$7.93
-0.14 (-1.73%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where NVAX is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
47 interventional · 8 with posted results
Held by 14 tracked-famous managers (D. E. Shaw & Co., Inc., TWO SIGMA INVESTMENTS, LP, COATUE MANAGEMENT LLC, MILLENNIUM MANAGEMENT LLC, CITADEL ADVISORS LLC, +9 more) · FINRA short interest 16.6 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Efficacy and Safety of NVX-CoV2705NCT07086222First episode of PCR-positive symptomatic COVID 19Randomized · Double-masked · Prevention | Phase 4 | Active, not recruiting | Biological: NVX-CoV2705, Placebo | COVID-19, Sars-CoV-2 Infection | 6,500 | 2026-11-18 | in 91 d | 2026-05-08 |
| A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination VaccineNCT06291857Numbers of participants with solicited local and systemic adverse events (AEs)Randomized · Single-masked · Prevention | Phase 3 | Completed | Biological: CIC Vaccine Co-formulated tNIV2 , SARSCoV-2 rS and Matrix-M Adjuvant, Novavax COVID-19 Vaccine, tNIV Vaccine, Fluzone High Dose | COVID-19 | 9,320 | 2025-12-24actual | — | 2026-06-05 |
| Lot Consistency Study of COVID-19 and Influenza Combination VaccineNCT06482359Numbers of participants with solicited local and systemic AEs.Randomized · Single-masked · Prevention | Phase 2/3 | Withdrawnsponsor's stated reason: It was decided to not move forward with the study. | Biological: coformulated CIC Vaccine, Fluzone HD trivalent | COVID-19, Influenza | 0 | 2025-11-16 | — | 2025-03-11 |
| Phase 3 Lot Consistency Study of Trivalent Hemagglutinin Nanoparticle Influenza VaccineNCT06485752Safety- Solicited AEs over 7 days post-vaccinationRandomized · Single-masked · Prevention | Phase 2/3 | Withdrawnsponsor's stated reason: Decided to not move forward with the study | Biological: tNIV 1 and Matrix-M Adjuvant | COVID-19 | 0 | 2025-02-04actual | — | 2025-03-11 |
| Impact of Reactogenicity of the 2024-2025 COVID-19 Vaccines on Health Care Workers and First Responders in the United StatesNCT06633835Percentage of participants with solicited systemic reactogenicity symptoms.Non-randomized · Open-label · Prevention | Phase 4 | Completed | Biological: protein subunit: Novavax COVID-19 vaccine, Pfizer mRNA COVID-19 vaccine | COVID-19, Vaccine-Preventable Diseases, SARS CoV 2 Infection | 660 | 2024-12-30actual | — | 2026-06-02 |
| A Strain Change Study for SARS-CoV-2 rS VaccinesNCT06409663Incidence, duration, and severity of solicited local and systemic adverse events (AEs)Open-label · Prevention | Phase 3 | Completed | Biological: NVX-CoV2705 Vaccine | Severe Acute Respiratory Syndrome Coronavirus 2 Infection | 60 | 2024-10-15actual | — | 2025-07-18 |
| Phase 2/3 Heterologous Boosting Study With Different Dose Levels of Monovalent SARS-CoV-2 rS VaccinesNCT05925127Immunogenicity index-Neutralizing antibody expressed as geometric mean titer ratio[GMTR ]against the Omicron subvariant XBB.1.5Randomized · Double-masked · Prevention | Phase 2/3 | Completed | Biological: NVX-CoV2373 (5μg), NVX-CoV2601 (5μg), NVX-CoV2601(5μg), NVX-CoV2601 (35μg), NVX-CoV2601(35μg), NVX-CoV2601(50μg), Bivalent BA.4/5 | COVID-19 | 994 | 2024-05-21actual | — | 2024-12-13 |
| Phase 3 Adolescent Study for SARS-CoV-2 rS Variant VaccinesNCT05973006results2025-07-15Participants With Solicited Local and Systemic AEs for 7 Days Following VaccinationRandomized · Double-masked · PreventionStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Biological: NVX-CoV2601 co-formulated Omicron XBB.1.5 SARS-CoV-2 rS vaccine, Prototype/XBB.1.5 Bivalent Vaccine (5 µg) | COVID-19 | 400 | 2024-04-01actual | — | 2025-07-15 |
| Study to Evaluate Safety and Immunogenicity of COVID-19 Vaccine in Children 6 Months to < 12 YearsNCT05468736Reactogenicity Incidence and SeverityRandomized · Triple-masked · Prevention | Phase 2/3 | Completed | Biological: SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period) · Other: Placebo | COVID-19 | 3,600 | 2024-01-16actual | — | 2026-05-22 |
| A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants.NCT05975060Part 1: Pseudovirus neutralization (inhibitory dilution at a concentration of 50%; ID 50 ) to the NVX-CoV2601 vaccineRandomized · Open-label · Prevention | Phase 2/3 | Completed | Biological: XBB.1.5 Vaccine (Booster), XBB.1.5 Vaccine (single dose) | COVID-19 | 660 | 2023-11-15actual | — | 2024-05-30 |
| Phase 3 Study of Novavax Vaccine(s) as Booster Dose After mRNA VaccinesNCT05875701results2025-06-26Neutralizing Antibody (Nab) for SARS-CoV-2 Wildtype Virus (Wuhan) Responses Expressed as Geometric Mean Titers (GMT)Randomized · Open-label · PreventionStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Biological: NVX-CoV2373, SARS-CoV-2 rS antigen/Matrix-M Adjuvant | COVID-19 | 147 | 2023-11-11actual | — | 2025-06-26 |
| A Study to Evaluate the Safety and Immunogenicity of COVID-19 and Influenza Combination VaccineNCT05519839Part 1 and Part 2 : Number of participants with solicited local and systemic Adverse Events (AEs)Randomized · Triple-masked · Prevention | Phase 2 | Completed | Drug: qNIV Vaccine with Matrix-M Adjuvant, Influenza Vaccine, CIC Vaccine with Matrix-M Adjuvant, SARS-CoV-2 rS Vaccine with Matrix-M Adjuvant · Other: Placebo Comparator | COVID-19, Influenza | 1,579 | 2023-07-25actual | — | 2024-07-16 |
| A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2NCT04611802Adult Main Study and Pediatric Expansion: Participants with Symptomatic Mild, Moderate, or Severe Coronavirus Disease 2019 (COVID-19)Randomized · Quadruple-masked · Prevention | Phase 3 | Completed | Biological: SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period), SARS-CoV-2 rS/Matrix-M1 Adjuvant (Crossover Vaccination period), SARS-CoV-2 rS/Matrix-M1 Adjuvant (Booster Vaccination), SARS-CoV-2 rS/Matrix-M1 Adjuvant (Second Booster Vaccination) · Other: Placebo (Initial Vaccination Period), Placebo (Crossover Vaccination period) | SARS-CoV Infection, Covid19 | 33,000 | 2023-04-10actual | — | 2023-12-21 |
| Evaluation of the Safety and Immunogenicity of SII Vaccine Constructs Based on the SARS-CoV-2 (COVID-19) Variant in AdultsNCT05029856MN50 GMTs to the SARS-CoV-2 B.1.351 (Beta) expressed as GMTRandomized · Quadruple-masked · Prevention | Phase 1/2 | Withdrawnsponsor's stated reason: Study never started | Biological: SII B.1.351, SII B.1.351, SII Bivalent, SII Bivalent, SII B.1.617.2 | Covid19 | 0 | Aug 2022 | — | 2022-05-31 |
| Study to Compare the Immunogenicity and Safety of 3 Lots of NVX-CoV2373 in AdultsNCT05463068results2026-04-17Serum Immunoglobulin G (IgG) Antibody Levels to the SARS-CoV-2 Spike Protein Expressed as Geometric Mean ELISA Unit [GMEUs]Randomized · Triple-masked · PreventionStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: NVX-Cov2373 | COVID-19, SARS-CoV-2 Infection | 911 | 2022-08-17actual | — | 2026-04-17 |
| Phase 3 Boosting Study for the SARS-CoV-2 rS Variant VaccinesNCT05372588Part 1: MN50 geometric mean titers (GMTs) to the Omicron BA.1 subvariant expressed as GMTsRandomized · Quadruple-masked · Prevention | Phase 3 | Completed | Drug: NVX-CoV2515, NVX-Cov2373, NVX-CoV2373 + NVX-CoV2515, NVX-CoV2540, NVX-CoV2373 + NVX-CoV2540 | COVID-19, SARS CoV 2 Infection | 1,340 | 2022-07-17actual | — | 2024-04-23 |
| Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS Nanoparticle Vaccine With/Without Matrix-M AdjuvantNCT04368988Participants with Solicited Adverse Events (AEs) - Phase 1Randomized · Quadruple-masked · Prevention | Phase 1/2 | Completed | Biological: SARS-CoV-2 rS - Phase 1, SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 1, SARS-CoV-2 rS/Matrix-M Adjuvant, Day 0 - Phase 1, SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 2 · Other: Normal saline solution (NSS), Placebo - Phase 1, Normal saline solution (NSS), Placebo - Phase 2, Normal saline solution (NSS), Placebo, Day 21 - Phase 1 | COVID-19 | 1,419 | 2022-06-01actual | — | 2023-04-10 |
| A Study to Evaluate Safety and Immunogenicity of a COVID-19 Vaccine in People Living With HIV at Risk for SARS-CoV-2 (COVID-19)NCT05112848Number of PLWH with unsolicited adverse events (AEs)Randomized · Quadruple-masked · Prevention | Phase 2 | Completed | Biological: NVX-CoV2373 | SARS-CoV-2 Infection | 384 | 2022-05-23actual | — | 2023-03-16 |
| A Study Looking at the Effectiveness, Immune Response, and Safety of a COVID-19 Vaccine in Adults in the United KingdomNCT04583995Participants with Symptomatic Mild, Moderate, or Severe Coronavirus Disease 2019 (COVID-19)Randomized · Quadruple-masked · Prevention | Phase 3 | Completed | Biological: SARS-CoV-2 rS/Matrix M1-Adjuvant, Licensed seasonal influenza vaccine · Other: Placebo | SARS-CoV-2 Infection, COVID-19 | 15,185 | 2022-03-29actual | — | 2025-05-08 |
| Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination VaccineNCT04961541results2025-04-10Number of Participants With Solicited Local and Systemic Adverse Events (AE's)Randomized · Triple-masked · PreventionStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Biological: ICC Vaccine, qNIV Nanoparticle Vaccine2 in-clinic mixed with Matrix-M1 Adjuvant, SARS-CoV-2 rS Nanoparticle Vaccine in-clinic mixed with Matrix-M1 Adjuvant | SARS-CoV Infection, Covid19 | 637 | 2021-12-22actual | — | 2025-04-10 |
| A Study Looking at the Effectiveness and Safety of a COVID-19 Vaccine in South African AdultsNCT04533399Cohort 1: HIV- Participants with Symptomatic Mild, Moderate, or Severe COVID-19Randomized · Quadruple-masked · Prevention | Phase 2 | Completed | Biological: SARS-CoV-2 rS/Matrix-M1 Adjuvant · Other: Placebo | SARS-CoV-2 Infection, COVID-19 | 4,422 | 2021-12-07actual | — | 2022-02-17 |
| Phase 3 Pivotal Trial of NanoFlu™ in Older AdultsNCT04120194results2023-05-06HAI Antibody Responses for Vaccine Homologous Influenza Strains Expressed as Ratio of Geometric Mean Fold Ratio (GMFR)Randomized · Quadruple-masked · PreventionStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Biological: NanoFlu, Fluzone Quadrivalent | Influenza, Human | 2,654 | 2020-10-29actual | — | 2023-05-06 |
| Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older AdultsNCT03658629results2022-11-04Number of Subjects With Adverse Events (AEs)Randomized · Quadruple-masked · PreventionStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: This study was terminated 182 days after initial dosing. | Biological: NanoFlu (Quad-NIV), Fluzone HD, Flublok Quadrivalent, Influenza Vaccine · Other: Matrix-M Adjuvant, Placebo | Influenza, Human | 1,375 | 2019-04-26actual | — | 2022-11-04 |
| A Study to Determine the Safety and Efficacy of the RSV F Vaccine to Protect Infants Via Maternal ImmunizationNCT02624947results2025-05-06Infants: Percentages of Participants With Medically Significant RSV LRTI With Either Hypoxemia (SpO2 <95% at Sea Level or <92% at Altitudes >1800 Meters) or TachypneaRandomized · Triple-masked · PreventionStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Biological: RSV F vaccine with adjuvant, Formulation buffer | Respiratory Syncytial Virus Infections | 4,636 | 2018-12-28actual | — | 2025-05-06 |
| Evaluation of the Safety and Immunogenicity of a Recombinant Trivalent Nanoparticle Influenza Vaccine With Matrix M-1 Adjuvant (NanoFlu)NCT03293498results2022-12-21Number of Participants With All Adverse Events (AEs), Medically Attended Adverse Events (MAAEs), Serious Adverse Events (SAEs), and Significant New Medical Conditions (SNMCs).Randomized · Triple-masked · PreventionStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Biological: NanoFlu, Fluzone HD - Day 0, Fluzone HD - Day 21 · Other: Saline - Day 21 | Influenza | 330 | 2018-03-14actual | — | 2022-12-21 |
| Safety and Immunogenicity Study to Evaluate Single- or Two-Dose Regimens Of RSV F Vaccine With and Without Aluminum Phosphate or Matrix-M1™ Adjuvants In Clinically-Stable Older AdultsNCT03026348Neutralizing antibody titers to at least one RSV/A strainRandomized · Quadruple-masked · Prevention | Phase 2 | Completed | Biological: RSV F Vaccine with Aluminum Phosphate Adjuvant, RSV F Vaccine, Matrix-M1 Adjuvant · Other: Phosphate Buffer | Respiratory Syncytial Viruses | 300 | Apr 2017actual | — | 2021-12-06 |
| A Study to Evaluate the Efficacy of an RSV F Vaccine in Older AdultsNCT02608502Numbers and percentages of subjects with moderate-severe RSV-LRTDRandomized · Triple-masked · Prevention | Phase 3 | Completed | Biological: RSV-F Vaccine, Phosphate Buffer Placebo | Respiratory Syncytial Virus (RSV) | 11,850 | Dec 2016actual | — | 2022-07-19 |
| Safety and Immunogenicity of the RSV-F Vaccine in Older Adults Previously Treated With the Same Vaccine or Placebo in the Prior Year.NCT02593071Serum IgG antibody concentrations as ELISA units (EUs) specific for the F protein antigen.Randomized · Triple-masked · Prevention | Phase 2 | Completed | Biological: RSV-F Vaccine, Phosphate Buffer Placebo | Respiratory Syncytial Virus (RSV) | 1,330 | Nov 2016actual | — | 2022-05-27 |
| RSV F Vaccine Maternal Immunization Study in Healthy Third-trimester Pregnant Women.NCT02247726Counts and percentage of subjects with solicited injection site and systemic reactogenicity within seven days of vaccination.Randomized · Triple-masked · Prevention | Phase 2 | Completed | Drug: Saline Placebo (0.5mL injection), RSV F vaccine (0.5mL injection) | Respiratory Syncytial Virus Infections | 50 | Jul 2016actual | — | 2022-05-27 |
| Study to Evaluate the Immunogenicity and Safety of an Ebola Virus (EBOV) Glycoprotein (GP) Vaccine in Healthy SubjectsNCT02370589Assessment of Adverse Events, SAEs, Medically Attended Events and Significant New Medical Conditions.Randomized · Double-masked · Prevention | Phase 1 | Completed | Biological: Base Dose EBOV GP Vaccine, 2x Base Dose EBOV GP Vaccine, 4x Base Dose EBOV GP Vaccine, 8x Base Dose EBOV GP Vaccine, Placebo, Matrix-M Adjuvant | Ebola | 230 | Apr 2016actual | — | 2021-11-24 |
| Placebo- Controlled Study to Evaluate the Safety and Immunogenicity of the RSV-F Vaccine in Elderly AdultsNCT02266628Immunogenicity as assessed by serum IgG antibody titers specific for the F-Protein antigenRandomized · Triple-masked · Prevention | Phase 2 | Completed | Biological: RSV-F Vaccine, Saline Placebo | Respiratory Syncytial Virus (RSV) | 1,599 | Mar 2016actual | — | 2022-05-27 |
| A Phase I Randomized, Observer-Blinded, Dose-Ranging Study in Healthy Subjects 24 to <72 Months of AgeNCT02296463Numbers and percentages of subjects with solicited local and systemic AEs.Randomized · Triple-masked · Prevention | Phase 1 | Completed | Biological: RSV F Vaccine with adjuvant (0.5mL injection), RSV F Vaccine (0.5mL injection), Hepatitis A Vaccine (0.5mL injection), Placebo (0.5mL injection) | Respiratory Synctial Virus | 32 | Sep 2015actual | — | 2016-04-28 |
| A(H7N9) VLP Antigen Dose-Ranging Study With Matrix-M1™ AdjuvantNCT02078674Assessment of SafetyRandomized · Triple-masked · Prevention | Phase 1/2 | Completed | Biological: Monovalent Avian Influenza VLP (H7N9), Matrix-M1™ adjuvant, Placebo | Influenza (Pandemic) | 610 | Jul 2015actual | — | 2016-09-23 |
| Quadrivalent Influenza VLP Vaccine Dose Ranging Study in Young AdultsNCT02307851Immunogenicity of the quadrivalent VLP vaccine using HAI responses.Randomized · Triple-masked · Prevention | Phase 2 | Completed | Biological: Quadrivalent VLP Vaccine, Comparator TIV | Influenza | 400 | Jun 2015actual | — | 2016-09-23 |
| A(H7N9) VLP Antigen Dose Ranging Study With Adjuvant 1NCT01897701Assessment of SafetyRandomized · Triple-masked · Prevention | Phase 1 | Completed | Biological: Monovalent Avian Influenza VLP (H7N9), Adjuvant 1, Placebo | Avian Influenza | 280 | Aug 2014actual | — | 2014-10-13 |
| RSV F Dose-Ranging Study in WomenNCT01960686Immunogenicity as assessed by serum IgG antibody titers specific for the F-Protein antigen across treatment groupsRandomized · Triple-masked · Treatment | Phase 2 | Completed | Biological: Low dose RSV F Antigen, High dose RSV F Antigen, Dose 1 of Aluminum Adjuvant, Dose 2 of Aluminum Adjuvant, Dose 3 of Aluminum Adjuvant, Dose 4 of Aluminum Adjuvant, Placebo | Respiratory Syncytial Virus Infections | 720 | Apr 2014actual | — | 2016-05-26 |
| RSV-F Vaccine and Influenza Vaccine Co-Administration Study in the ElderlyNCT01709019Assessment of SafetyRandomized · Triple-masked · Prevention | Phase 1 | Completed | Biological: Low dose RSV-F Vaccine with Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28), Low dose RSV-F Vaccine without Adjuvant (Day 0); Seasonal TIV (Day 0 & day 28), High dose RSV-F Vaccine with Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28), High dose RSV-F Vaccine without Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28), Placebo (Day 0 & Day 28); Seasonal TIV (Day 0) | Respiratory Syncytial Virus (RSV) | 220 | Jul 2013actual | — | 2014-03-05 |
| RSV-F Vaccine Dose Ranging Study in Young WomenNCT01704365Immunogenicity as assessed by serum IgG antibody titers specific for the F-Protein antigen across treatment groupsRandomized · Triple-masked · Treatment | Phase 2 | Completed | Biological: Low dose RSV-F Vaccine with Adjuvant, Low dose RSV-F Vaccine without Adjuvant, High dose RSV-F Vaccine with Adjuvant, High dose RSV-F Vaccine without Adjuvant, Low dose RSV-F Vaccine with Adjuvant [Bedside Mixing], Placebo | Respiratory Syncytial Virus (RSV) | 330 | Apr 2013actual | — | 2014-03-07 |
| A Study to Evaluate the Immune Response and Safety of a Seasonal Virus-Like Particle Influenza Vaccine in Healthy Young AdultsNCT01561768Immunogenicity of 3 dose levels of the Novavax Quadrivalent vaccine based on HAI responsesRandomized · Triple-masked · Prevention | Phase 2 | Completed | Biological: Novavax Quadrivalent vaccine, Novavax Quadrivalent vaccine, Novavax Quadrivalent vaccine, Novavax Trivalent vaccine, cTIV | Influenza | 500 | Jan 2013actual | — | 2013-07-18 |
| A/H5N1 Virus-Like Particle Antigen Dose Ranging Study With Adjuvant 2NCT01596725Number of solicited and unsolicited adverse events in H5N1 VLP antigen dose groups delivering HA with/without Adjuvant 2.Randomized · Triple-masked · Prevention | Phase 1 | Completed | Biological: Monovalent Avian Influenza VLP (H5N1), Monovalent Avian Influenza VLP (H5N1), Monovalent Avian Influenza VLP (H5N1); Adjuvant, Monovalent Avian Influenza VLP (H5N1); Adjuvant, Monovalent Avian Influenza VLP (H5N1); Adjuvant, Saline Placebo | Influenza (Pandemic) | 333 | Aug 2012actual | — | 2014-02-06 |
| A/H5N1 Virus-Like Particle Antigen Dose Ranging Study With Adjuvant 1NCT01594320Number of solicited and unsolicited adverse events in H5N1 VLP antigen dose groups delivering HA with/without Adjuvant 1.Randomized · Triple-masked · Prevention | Phase 1 | Completed | Biological: Monovalent Avian Influenza VLP (H5N1), Monovalent Avian Influenza VLP (H5N1), Monovalent Avian Influenza VLP (H5N1); Adjuvant, Monovalent Avian Influenza VLP (H5N1); Adjuvant, Monovalent Avian Influenza VLP (H5N1); Adjuvant, Saline placebo | Influenza (Pandemic) | 333 | Jul 2012actual | — | 2014-02-06 |
| Safety and Immunogenicity of an A (H1N1) 2009 Influenza Virus-like Particle (VLP) VaccineNCT01072799Safety and tolerability of two injections of A (H1N1) 2009 influenza VLP vaccineRandomized · Quadruple-masked · Prevention | Phase 2 | Completed | Biological: Placebo, A/H1N1 2009 Influenza VLP Vaccine | Seasonal Influenza | 4,560 | Mar 2012actual | — | 2012-04-25 |
| Safety Study of Respiratory Syncytial Virus (RSV)-Fusion (F) Protein Particle VaccineNCT01290419To assess and compare the safety, reactogenicity, and tolerability of 6 RSV-F protein particle vaccine formulations.Randomized · Double-masked · Treatment | Phase 1 | Completed | Biological: RSV-F Particle Vaccine, RSV-F Particle Vaccine, RSV-F Particle Vaccine, RSV-F Particle Vaccine, Placebo, RSV-F Particle Vaccine, RSV-F Particle Vaccine | Respiratory Syncytial Virus Infections | 150 | Dec 2011actual | — | 2012-03-08 |
| Evaluate the Safety and Immunogenicity of a Seasonal Influenza Virus-Like Particle (VLP) Vaccine in Older AdultsNCT01014806Adverse Events (AEs)Randomized · Quadruple-masked · Prevention | Phase 2 | Completed | Biological: Influenza VLP Vaccine, TIV | Influenza | 467 | May 2010actual | — | 2013-07-18 |
| Trial to Evaluate Safety and Immunogenicity of Trivalent Seasonal Influenza Virus-Like Particle (VLP) Vaccine (Recombinant)NCT00903552To assess the tolerability and safety of the Influenza VLP VaccineRandomized · Quadruple-masked · Prevention | Phase 2 | Completed | Biological: Influenza VLP Vaccine, Placebo | Seasonal Influenza | 221 | Oct 2009actual | — | 2013-07-18 |
| Evaluate the Safety and Immunogenicity of a Seasonal Influenza VLP Vaccine (Recombinant) in Healthy AdultsNCT00754455To assess the tolerability and safety of Influenza VLP VaccineRandomized · Double-masked · Prevention | Phase 2 | Completed | Biological: Influenza VLP Vaccine (recombinant), Placebo | Influenza | 317 | Mar 2009actual | — | 2013-07-18 |
| Safety, Reactogenicity and Immunogenicity of an H5N1 VLPNCT00519389Safety and reactogenicity of H5N1 VLP VaccineRandomized · Quadruple-masked · Prevention | Phase 1/2 | Completed | Biological: H5N1 VLP Vaccine, Placebo | Pandemic Influenza | 230 | Nov 2008actual | — | 2013-06-21 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19